论文部分内容阅读
为了开发一种新型高效的维甲类抗癌药物,在无水、无氧、避光条件下合成了维甲酸镍的配合物,通过元素分析、摩尔电导、红外光谱、紫外光谱、差热及核磁共振氢谱测定了配合物的组成、结构和性质,其分子式为Ni(RA)2·3H2O.采用MTT比色法、克隆形成法及NBT还原试验分别研究了该配合物及全反式维甲酸(ATRA)对HL 60细胞增殖及分化的影响.结果表明,二者均能抑制HL 60细胞增殖并诱导其分化,尤其该配合物的作用明显强于全反式维甲酸(p<0.01).同时采用MTT比色法研究了维甲酸与配合物对正常Vero细胞的毒性,发现配合物对该细胞生长无明显抑制作用,与对照组相比p>0.05.
In order to develop a novel and effective anti-cancer drug of dimension A, a nickel (IV) complex was synthesized under anhydrous, anaerobic and dark conditions. The complex was characterized by elemental analysis, molar conductance, IR, UV, The composition, structure and properties of the complex were determined by 1H-NMR and the formula was Ni (RA) 2 · 3H2O. The complexes and all-trans-dimension were studied by MTT assay, (ATRA) on the proliferation and differentiation of HL-60 cells.The results showed that both of them could inhibit the proliferation and induce the differentiation of HL-60 cells, especially the effect of this complex was stronger than that of all-trans retinoic acid (p <0.01) At the same time, MTT colorimetry was used to study the toxicity of retinoic acid and its complex to normal Vero cells. The results showed that there was no significant inhibitory effect of the complex on the growth of the cells, p> 0.05 compared with the control group.